Health Care: Drugs

Celgene Corp (CELG: NASDAQ)

$134.23 n/a | n/a%
06/28/17 - 04:00 PM ET
Company Profile
Price and Volume
Recent Price 134.23
52 Week High 135.18
52 Week Low 96.93
Avg. Daily Vol. (Mil) 3.93
Beta (3 year) 1.51
Share Related Items
Mkt Cap (Mil) 104,810.05
Shares Out (Mil) 780.82
Float (Mil) 778.89
Dividend Information
Yield % 0.00
Annual Dividend 0.00
Payout Ratio 0.00
Financial Strength
Quick Ratio 4.00
Current Ratio 4.40
LT Debt/ Equity 1.80
Total Debt / Equity 1.87
Valuation Ratios
Price Earnings 50.50
Price/Sales 8.98
Price/Book 13.71
Price/Cash Flow 39.70
Per Share Data
Earnings 2.66
Sales 14.96
Book Value 9.79
Cash Flow 3.38
Business Summary
Celgene Corp is a biotech company that discovers, develops, and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. Its registered brands are Abraxane, Istodax, Otezla, Pomalyst, Revlimid, Thalomid, Vidaza.
General Information
86 Morris Avenue
Summit, NJ 07901
www.celgene.com
Industry : Drugs
Sector: Health Care
Employees: 7132
CEO: Mark J. Alles
Short Interest
Current Month (Mil) 10.02
Previous Month (Mil) 9.48
Short Interest Ratio (Days) 2.70
Management Effectiveness
Return on Equity 28.00
Return on Assets 7.40
Return on Investments 10.00
Profitability
Gross Margin 96.60
EBIT Margin 25.50
Profit Margin 18.30

Portfolios with CELG

Latest CELG Headlines from TheStreet

More Financial News for CELG

Press Releases for CELG

See All Press Releases
brokerage partners
watch thestreet tv
No Videos Found
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter